151 related articles for article (PubMed ID: 21448089)
1. Quantitative imaging characterization of hypersecreting or nonhypersecreting adrenal adenomas: comparison between iodine-131 norcholesterol uptake and magnetic resonance signal intensity ratios.
Maurea S; Imbriaco M; Mollica C; Pace L; Salvatore M
Nucl Med Commun; 2011 Jun; 32(6):535-41. PubMed ID: 21448089
[TBL] [Abstract][Full Text] [Related]
2. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques.
Maurea S; Caracò C; Klain M; Mainolfi C; Salvatore M
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):188-97. PubMed ID: 15499292
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses.
Maurea S; Klain M; Mainolfi C; Ziviello M; Salvatore M
J Nucl Med; 2001 Jun; 42(6):884-92. PubMed ID: 11390552
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of radionuclide imaging using 131I nor-cholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours.
Maurea S; Klain M; Caraco C; Ziviello M; Salvatore M
Nucl Med Commun; 2002 Oct; 23(10):951-60. PubMed ID: 12352593
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas.
Yoh T; Hosono M; Komeya Y; Im SW; Ashikaga R; Shimono T; Tsuchiya N; Okada M; Hanada K; Yagyu Y; Nishimura Y; Murakami T
Ann Nucl Med; 2008 Jul; 22(6):513-9. PubMed ID: 18670858
[TBL] [Abstract][Full Text] [Related]
6. Case report: failure of adrenal scintigraphy to exhibit 131I cholesterol uptake in a CT-demonstrated, surgically proven aldosteronoma.
Salam Z; Lubbos H; Martinez C; Mozley PD; Miller JL; Rose LI
Am J Med Sci; 1996 Sep; 312(3):130-2. PubMed ID: 8783680
[TBL] [Abstract][Full Text] [Related]
7. [The role of adrenal gland x-ray computed tomography and scintigraphy using radiolabelled norcholesterol in the etiological diagnosis of primary hyperaldosteronism].
Abram M; Peltier P; Murat A; Chupin M; Dupas B; Gaillard F; Chatal JF; Charbonnel B
Rev Med Interne; 1993; 14(7):691-7. PubMed ID: 8191071
[TBL] [Abstract][Full Text] [Related]
8. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors.
Bilbey JH; McLoughlin RF; Kurkjian PS; Wilkins GE; Chan NH; Schmidt N; Singer J
AJR Am J Roentgenol; 1995 Mar; 164(3):637-42. PubMed ID: 7863885
[TBL] [Abstract][Full Text] [Related]
9. [Scintigraphic characterization of expansive lesions located in the adrenals. Comparison with magnetic resonance imaging].
Maurea S; Klain M; Lastoria S; Caracò C; Castelli L; Varrella P; Filice S; Rossi R; Salvatore M
Radiol Med; 1995 Dec; 90(6):756-65. PubMed ID: 8685460
[TBL] [Abstract][Full Text] [Related]
10. Contralateral adrenal suppression on adrenocortical scintigraphy provides good evidence showing subclinical cortisol overproduction from unilateral adenomas.
Katabami T; Ishii S; Obi R; Asai S; Tanaka Y
Endocr J; 2016 Dec; 63(12):1123-1132. PubMed ID: 27616151
[TBL] [Abstract][Full Text] [Related]
11. MR imaging of the adrenal neoplasms.
Siegelman ES
Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):769-86. PubMed ID: 11149679
[TBL] [Abstract][Full Text] [Related]
12. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses.
Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J
Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic dilemma of small incidentally discovered adrenal masses: role for 131I-6beta-iodomethyl-norcholesterol scintigraphy.
Kloos RT; Gross MD; Shapiro B; Francis IR; Korobkin M; Thompson NW
World J Surg; 1997 Jan; 21(1):36-40. PubMed ID: 8943175
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the large adrenal mass.
Khafagi FA; Gross MD; Shapiro B; Glazer GM; Francis I; Thompson NW
Br J Surg; 1991 Jul; 78(7):828-33. PubMed ID: 1873713
[TBL] [Abstract][Full Text] [Related]
15. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates.
Barzon L; Scaroni C; Sonino N; Fallo F; Gregianin M; Macrì C; Boscaro M
J Clin Endocrinol Metab; 1998 Jan; 83(1):55-62. PubMed ID: 9435416
[TBL] [Abstract][Full Text] [Related]
16. Characterization of adrenal masses (< 5 cm) by use of chemical shift MR imaging: observer performance versus quantitative measures.
Mayo-Smith WW; Lee MJ; McNicholas MM; Hahn PF; Boland GW; Saini S
AJR Am J Roentgenol; 1995 Jul; 165(1):91-5. PubMed ID: 7785642
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of chemical-shift MR imaging to differentiate between adrenal adenomas and non adenoma adrenal lesions.
Maurea S; Imbriaco M; D'Angelillo M; Mollica C; Camera L; Salvatore M
Radiol Med; 2006 Aug; 111(5):674-86. PubMed ID: 16791464
[TBL] [Abstract][Full Text] [Related]
18. [Iodo-methyl norcholesterol scintigraphy in the localization of primary hyperaldosteronism].
Khalil SA; Julien J; Pagny JY; Jeunemaitre X; Bouarfa N; Plouin PF; Corvol P
Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1233-5. PubMed ID: 2510654
[TBL] [Abstract][Full Text] [Related]
19. Role of molecular imaging in management of nonhypersecreting adrenal masses.
Lawson MA
J Nucl Med; 2001 Jun; 42(6):893-4. PubMed ID: 11390553
[No Abstract] [Full Text] [Related]
20. SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma.
La Cava G; Imperiale A; Olianti C; Gheri GR; Ladu C; Mannelli M; Pupi A
J Nucl Med; 2003 Jul; 44(7):1057-64. PubMed ID: 12843220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
